Power3 Principals Patent Stem Cell Breakthrough Identifying Protein Biomarkers Which Scientists Expect to be the Gold Standard for Future Stem Cell Therapy

Tuesday May 4, 2010, 11:28 am EDT

HOUSTON--(BUSINESS WIRE)--StemTroniX, Inc., a Texas corporation, and Power3 Medical Products, Inc. (OTCBB: PWRM – News) announced today that a joint provisional patent application entitled, “Stem Cell Protein Biomarkers and Their Use in Monitoring Stem Cells and Their Products for Stem Cell Therapy” has been filed by the principals of StemTroniX and Power3 with the United States Patent and Trademark Office. The patent application covers the convergence of technologies at StemTroniX and Power3 in anticipation of the upcoming acquisition of StemTroniX by Power3.

The provisional patent application discloses technologies designed to enhance the therapeutic process capabilities through the identification of the patients’ own stem cells. This patent application will be assigned by the inventors to the surviving public entity, to be named “StemTroniX,” upon the closing of the acquisition of StemTroniX by Power3.

“The filing of this provisional patent application with the USPTO is a welcome milestone for us,” said Helen R. Park, Chief Executive Officer of Power3. “It clearly claims and evidences in no uncertain terms how medical practices and scientific methods will enhance modern and future regenerative medicine technologies by precisely identifying the specific stem cells to be transplanted with protein biomarkers. This patent application provides us with an opportunity to enhance effectiveness of stem cell therapy and broaden its application.”

While in France to deliver his plenary address to the “European Molecular Histopathology Symposium on the Impact of Personalized Medicine,” Dr. Goldknopf, the President and Chief Scientific Officer of Power3, presented some newly discovered results that demonstrate how to apply this breakthrough technology to patient selection, stem cell selection, and modifications for treatment of different forms of Alzheimer’s disease. In an interview, Dr. Goldknopf stated that during the week of May 10, 2010, he intends to publicly disclose, in a world wide press release, how this entirely novel, patent pending breakthrough was surprisingly discovered by him while studying the effect of the human genome and its protein identifiers on responses to drug treatment. “I believe that this will become a new paradigm for personalized, regenerative therapy of patients with their own stem cells,” stated Dr. Goldknopf. “This new approach underscores the synergy behind the impending acquisition of StemTroniX by Power3.”

“StemTroniX has a wealth of complementary adult stem cell therapy technology, know-how and experience,” added Dr. Goldknopf. “Its patent portfolio includes a licensed patent and several patent disclosures for monitoring of stem cell therapy, technology to aid in the viability of adult stem cells, injection technology, and non-invasive imaging technology. We see the filing of this provisional patent application as a significant first step towards achieving our joint goal, which is to fulfill the promise of personalized medicine by providing desperately needed diagnosis and targeted therapy for neurodegenerative disease, heart disease and cancer.”

Power3 Medical Products

Power3 Medical Products, Inc. is a leader in bio-medical research and the commercialization of biomarkers, tests, and mechanisms of disease. Power3's patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and prognosis of disease, identify protein biomarkers, and drug targets, to fulfill critical unmet needs in areas including neurodegenerative disease (NuroPro®) and breast cancer (BC-SeraPro™). Power3 operates a state-of-the-art CLIA certified laboratory in The Woodlands (Houston), Texas and continues to evolve and enhance its IP portfolio, employing sensitive and specific combinations of biomarkers blood-based tests for ALS, Alzheimer's, and Parkinson's diseases, breast cancer, and drug resistance.

For more information visit, www.Power3Medical.com

StemTroniX

StemTroniX, Inc. is a medical biotechnology company that is committed to improving the lives of individuals by using autologous adult stem cell technology to repair tissue damage in patients. Autologous adult stem cell therapy is the process of using an individual's own stem cells for the purpose of repairing and regenerating damaged tissue. StemTroniX also provides a patented system to augment this process in a non-invasive method for in-body monitoring of the stem cells at the site of injury as they are being introduced into the patients.

For more information visit, www.stemtronix.com

Safe Harbor Provision

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact contained herein, including, without limitation, statements regarding the company's future financial position, business strategy, budgets, projected revenues and costs, and plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "may," "will," "expects," "intends," "plans," "projects," "estimates," "anticipates," or "believes" or the negative thereof or any variation thereon or similar terminology or expressions. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from results proposed in such statements. Although the company believes that the expectations reflected in such forward-looking statements are reasonable, it can provide no assurance that such expectations will prove to have been correct. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors set forth in the company's Annual Report on Form 10-K for the year ended December 31, 2009 and its other filings and submissions with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date made. Except as required by law, the company assumes no obligation to update or revise any of the information contained in this press release.

Contact:

Crown Equity Holdings, Inc.
Ken Bosket
(877) 854-6797
(702) 448-1543